With a market cap of\u00a0$694.9 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876, it is renowned for developing innovative medicines in areas such as diabetes, oncology, immunology, neuroscience, and obesity management.<\/p>\n
Companies valued over $200 billion are generally described as \u201cmega-cap\u201d stocks, and Eli Lilly fits right into that category. The company has a strong research and development focus, investing heavily in next-generation biologics, oncology therapies, and treatments for neurodegenerative diseases such as Alzheimer\u2019s. It is also expanding in immunology and rare diseases through acquisitions and strategic collaborations.<\/p>\n
However,\u00a0the pharma giant has declined 24.5% from its\u00a052-week high of $969.65 on Sept. 3. Over the past three months,\u00a0its shares have dipped 1.8%, lagging behind the Health Care Select Sector SPDR Fund’s (XLV)\u00a03.8% rise\u00a0over the same time frame.<\/p>\n
www.barchart.com <\/p>\n
Longer term,\u00a0the pharmaceutical giant is down 5.2% on a YTD basis, lagging behind XLV\u2019s marginal decrease. Moreover, shares of\u00a0Eli Lilly have declined nearly 22.9% over the past 52 weeks, compared to\u00a0XLV\u2019s 12.4% dip\u00a0over the same time frame.<\/p>\n
LLY has been in a bearish trend, trading mostly below its 50-day and 200-day moving averages since the end of May.<\/p>\n
www.barchart.com <\/p>\n
On Aug. 1, Eli Lilly\u2019s\u00a0stock gained over 2% after The Washington Post reported that the U.S. government plans to launch a five-year pilot program enabling Medicare and Medicaid coverage for costly GLP-1 weight-loss drugs, including\u00a0Mounjaro and Zepbound. The program, led by the CMS Innovation Center, is set to begin in April 2026 for Medicaid and January 2027 for Medicare.<\/p>\n
Furthermore, LLY has lagged behind its rival, Johnson & Johnson (JNJ), which experienced a\u00a021.3% YTD gain\u00a0and a 7% rise over the past 52 weeks.<\/p>\n
Nevertheless, the stock has a consensus rating of \u201cStrong Buy\u201d from 27 analysts in coverage, and\u00a0the mean price target of $906.50 represents a 23.8% premium to the current market prices.<\/p>\n
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on Barchart.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"With a market cap of\u00a0$694.9 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company headquartered…\n","protected":false},"author":2,"featured_media":36892,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[18,1465,135,475,4785,474,19,17,28625,28626,28627],"class_list":{"0":"post-36891","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-eire","9":"tag-eli-lilly","10":"tag-health","11":"tag-health-care","12":"tag-health-care-select-sector-spdr-fund","13":"tag-healthcare","14":"tag-ie","15":"tag-ireland","16":"tag-pharmaceutical-company","17":"tag-pharmaceutical-giant","18":"tag-sergio-photone"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/36891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=36891"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/36891\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/36892"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=36891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=36891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=36891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}